RxDoctor Payments Data

Christos Sidiropoulos, MD

Neurology · East Lansing, MINPI 1972794774

Payments from drug & device makers

$107,194in general payments, 2019–2025

Across 125 payments — averaging $857.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$74K
  • Neurocrine Biosciences, Inc.$15K
  • Biohaven Pharmaceuticals, Inc.$8K
  • Boston Scientific$6K
  • Acorda Therapeutics, Inc$2K
  • Medtronic$601
  • plus $2K from 18 others

What the payments were for

  • Consulting fees$14,82972%
  • Speaking & faculty fees$5843%
  • Travel & lodging$2,04710%
  • Food & beverage$3,25216%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$107,194 in reported general payments places this provider in the 85th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$7,244
Medicare patients
37
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa43$95,942
Rivastigmine29$9,623
Carbidopa-LevodopaCarbidopa/Levodopa72$8,240
Carbidopa-Levodopa ErCarbidopa/Levodopa30$2,311
AmantadineAmantadine Hcl25$1,987
Mirtazapine28$1,163
Donepezil Hcl31$1,011
Memantine Hcl20$866
Ropinirole Hcl13$499
Quetiapine Fumarate25$461
Gabapentin25$439
Citalopram HbrCitalopram Hydrobromide17$279
Primidone12$263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$89$95,94243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 652 neurology providers in Michigan.

Other neurology in East Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →